Your browser doesn't support javascript.
Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study.
Shacham-Shmueli, Einat; Itay, Amit; Margalit, Ofer; Berger, Raanan; Halperin, Sharon; Jurkowicz, Menucha; Levin, Einav G; Levy, Itzchak; Olmer, Liraz; Regev-Yochay, Gili; Lustig, Yaniv; Rahav, Galia.
  • Shacham-Shmueli E; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel. Electronic address: Einat.shmueli@sheba.health.gov.il.
  • Itay A; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel.
  • Margalit O; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel.
  • Berger R; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel.
  • Halperin S; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Jurkowicz M; Department of Oncology, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Levin EG; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel; The Infectious Diseases Unit, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Levy I; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel; The Infectious Diseases Unit, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Olmer L; Bio-statistical and Bio-mathematical Unit, The Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Regev-Yochay G; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel; The Infectious Diseases Unit, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
  • Lustig Y; Central Virology Laboratory, Public Health Services, Ministry of Health, Sheba Medical Center, Tel Hashomer, Israel.
  • Rahav G; Sackler Faculty of Medicine, Tel-Aviv University, P.O.B 39040. Ramat Aviv Tel Aviv Israel; The Infectious Diseases Unit, Sheba Medical Center, Derech Sheba 2, Tel-Hashomer, Ramat Gan, Israel.
Eur J Cancer ; 160: 285-286, 2022 01.
Article in English | MEDLINE | ID: covidwho-1603064
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: BNT162 Vaccine / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: BNT162 Vaccine / Neoplasms Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article